Pathology in Japan: Prostate Cancer

• Publication date: December 2010

The report provides comprehensive data on prostate cancer, highlighting the treatment guidelines. It identifies and analyzes the major industry developments shaping and driving the Japanese prostate cancer therapeutics industry, and analyzes the treatment usage patterns. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing industry leaders. The repo...

The report provides comprehensive data on prostate cancer, highlighting the treatment guidelines. It identifies and analyzes the major industry developments shaping and driving the Japanese prostate cancer therapeutics industry, and analyzes the treatment usage patterns. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing industry leaders. The report provides valuable insights into the new product development within the global prostate cancer segment . It quantifies the unmet need in the Japanese prostate cancer therapeutics industry, highlighting the opportunity for future players.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Industry expert's team of market experts.

Research Scope

The scope of the report includes:
- An overview of prostate cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized Japanese prostate cancer therapeutics industry revenue, annual cost of therapy and treatment usage patterns data (for hormone therapy and hormone resistant or refractory therapy) from 2001 to 2009, projection for 11 years to 2020.
- Insightful review of the key market drivers, restraints and challenges and predicted impact of key events.
- Competitor assessment including drug launch analysis and drug sales projections .
- Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, LCM (Life Cycle Management) activities and drug sales projection .
- Analysis of unmet need in the industry and target product profiles including opportunity for target products.
- Technology trends analytic framework to assess the strength of the pipeline.
- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include EGFR inhibitors, VEGF inhibitors, tyrosine kinase inhibitor, angiogenesis inhibitors and others.
- An overview of the most promising drugs including clinical study details, efficacy, safety, collaboration agreements, industry ing rights and launch analysis.
- Analysis of the current and future industry competition in the Japanese Prostate Cancer therapeutics industry . Firms profiles including business description, financial overview and SWOT analysis. Key future industry players covered include Sanofi-aventis, Pfizer, Inc., AstraZeneca PLC, Bristol-Myers Squibb, Medivation, Takeda Pharmaceuticals and Dendreon Corporation.
- Analysis of licensing agreements during 2004-2010 in the prostate cancer therapeutics industry . Merger and Acquisition (M&A analysis) which includes Merger and Acquisition deals by size and geography.
- Strategic assessment of the industry through industry impact analysis, future industry scenario and industry player analysis.
- Direct quotes from key opinion leaders (KOL) or physicians in the prostate cancer therapeutics industry in Japan.

Why Should You Get This Report?

The report will enhance your decision making capability. It will allow you to:
- Develop business strategies and perform superior industry quantification analysis by
- Understanding the trends shaping and driving the Japanese prostate cancer therapeutics industry .
- Understanding the treatment preferences of physicians for each disease state and across treatment flow.
- Accessing industry sizing projections and quantified growth opportunities in the Japanese prostate cancer therapeutics industry up to 2020.
- Quantifying the patient population in the Japanese to better design product pricing and launch plans.
- Drive revenues, formulate effective sales and industry ing strategies and gain in-depth understanding of the competitive landscape by
- Performing benchmarking analysis and growth opportunities against currently industry ed products.
- Identifying industry entry points based on safety, efficacy, and pricing parameters.
- Assessing competitiveness of products in the industry by understanding the strengths and weaknesses of current competition.
- Develop and design your in-licensing and out-licensing strategies by
- Taking a comprehensive look at the disease pipeline and identifying the most promising paradigm-shifting products.
- Assessing the strength of pipeline based on first-in-class, me-too and generic products and their lifecycle management.
- Track drug sales in the Japanese prostate cancer therapeutics industry from 2001 to 2020.
- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and industry ing efforts by identifying the industry categories and sectors that present the best opportunities for consolidation, investments and strategic partnerships.
- What’s the next big thing in the Japanese prostate cancer therapeutics industry landscape? Identify, understand and decide.

Therapy Industry in Japan

1 Table of Contents 4
I. 1 List of Data tables 7
I. 2 List of Charts 8
2 Disease Data 10
II. 1 Overview 10
II. 1.1 TNM (Tumor, Nodes, Metastasis) Staging System 10
II. 1.2 Jewett-Whitmore system 11
II. 2 Epidemiology 12
II. 3 Etiology 12
II. 4 Symptoms 12
II. 4.1 Localized or Locally Advanced Prostate Cancer 12
II. 4.2 Metastatic Prostate Cancer 13
II. 5 Diagnosis 13
II. 5.1 Digital Rectal Examination 13
II. 5.2 Prostate Specific Antigen Test 14
II. 5.3 Transrectal Ultrasound 14
II. 5.4 Prostate Biopsy 14
II. 6 Pathology 15
II. 6.1 Grading 15
II. 7 Treatment 15
II. 7.1 Watchful Waiting 15
II. 7.2 Radiation therapy 15
II. 7.3 Surgery 16
II. 7.4 Hormone therapy 17
II. 7.5 Chemotherapy Options 18
II. 7.6 Other Treatments Being Studied 18
II. 8 Treatment Guidelines 19

III March ket Characterization 20
III. 1 Japan 20
III. 1.1 March ket Size 20
III. 1.2 Drivers and Barriers 25
III. 1.3 Impact on the March ket 26
III. 1.4 Forecasted data s 27
III. 1.5 Future Impact 32
III. 1.6 Drug Sales 33
III. 1.7 Pricing & Reimbursements 37

IV Competitor Assessment 38
IV. 1 Strategic Competitor Assessment 38
IV. 1.1 Overview 38
IV. 1.2 Benchmarking 39
IV. 1.3 Current Competitor Assessment 43
IV. 2 Launch Analysis and Sales Forecasted data s 45
IV. 3 Product Profiles 46
IV. 3.1 Taxotere (docetaxel) 47
IV. 3.2 Casodex (Bicalutamide) 51
IV. 3.3 Zoladex (Goserelin) 56
IV. 3.4 Lupron (Leuprolide acetate) 58
IV. 3.5 Firmagon (degarelix) 62
IV. 3.6 November antrone (Mitoxantrone hydrochloride) 65
IV. 3.7 Emcyt (estramustine) 67
IV. 3.8 Trelstar (triptorelin) 69
IV. 3.9 Eulexin 70
IV. 3.10 Delestrogen 72
IV. 3.11 Gynodiol 74
IV. 3.12 Estrace tablet 75
IV. 3.13 Tace 76
IV. 3.14 Nilandrone 77
IV. 3.15 Premarin 78
IV. 3.16 Sales Forecasted data for Trelstar, December apeptyl, Gonapeptyl, Flutamide, Estradiol 79

V Pipeline Assessment 80
V. 1 Overview 80
V. 2 Pipeline Analysis by Phase of Development 81
V. 3 Pipeline by Mechanism of Action 82
V. 4 Strategic Pipeline Assessment 83
V. 4.1 Technology Trends Analytical Framework 83
V. 5 Trends in Prostate Cancer Pipeline 84
V. 5.1 More Clarity on the Origin of Prostate Cancer Will Help in Identifying November el Targets for Prostate Cancer Drugs 84
V. 5.2 Molecules with November el Mechanism of Action Strengthening Prostate Cancer Pipeline 84
V. 5.3 Failure of Key Molecules to Achieve Positive Results in Phase III Development 84
V. 6 Partners in Research and Development 85
V. 6.1 Licensing Agreements by Phase of Development 85
V. 6.2 Licensing Agreements by Geography 88
V. 6.3 Licensing Agreements: Technology Licensing Agreements in Prostate Cancer 88
V. 7 Most Promising Drugs’ Profiles 89
V. 7.1 Provenge (sipuleucel-T) 91
V. 7.2 Jevtana (cabazitaxel) 93
V. 7.3 Aflibercept (VEGF Trap) 95
V. 7.4 Ipilimumab 97
V. 7.5 Abiraterone Acetate (CB7630) 100
V. 7.6 Zibotentan (ZD4054) 102
V. 7.7 Sprycel (dasatinib) 104
V. 7.8 MDV3100 106
V. 8 Prostate Cancer Pipeline – Pre-clinical Phase 109
V. 9 Prostate Cancer Pipeline – Phase I 111
V. 10 Prostate Cancer Pipeline – Phase II 114
V. 11 Prostate Cancer Pipeline – Phase III 123
V. 12 Key Takeaway 125

VI Unmet Need and Target Product Profile 126
VI. 1 Unmet Need 128
VI. 1.1 Hormone-independent Metastatic Prostate Cancer Therapy 128
VI. 1.2 Hormone-dependent Metastatic Prostate Cancer Therapy 129
VI. 2 Opportunity for Target Product 130
VI. 3 Target Product Profile 132
VI. 3.1 Ideal Characteristics 132
VI. 3.2 Target Product Description 133
VI. 4 Key Takeaway 133

VII Strategic Assessment 134
VII. 1 Key Events Impacting the Future March ket 134
VII. 2 March ket Impact Analysis 135
VII. 3 Future March ket Scenario 135
VII. 4 Firms Analysis 137
VII. 4.1 March ket Leadership 137
VII. 4.2 Future Players in the March ket 137
VII. 5 Key Takeaway 138

VIII Company Profiles 139
VIII. 1 Sanofi-aventis 139
VIII. 1.1 Business Overview 139
VIII. 1.2 Financial Overview 141
VIII. 1.3 SWOT 141
VIII. 1.4 Oncology Focus 146
VIII. 2 Pfizer Inc. 147
VIII. 2.1 Business Overview 147
VIII. 2.2 Financial Overview 148
VIII. 2.3 SWOT 148
VIII. 2.4 Oncology Focus 154
VIII. 3 AstraZeneca 156
VIII. 3.1 Business Overview 156
VIII. 3.2 Financial Overview 157
VIII. 3.3 SWOT 158
VIII. 3.4 Oncology Focus 162
VIII. 4 Bristol-Myers Squibb 164
VIII. 4.1 Business Overview 164
VIII. 4.2 Financial Overview 165
VIII. 4.3 SWOT 165
VIII. 4.4 Oncology Focus 171
VIII. 5 Medivation 172
VIII. 5.1 Business Overview 172
VIII. 5.2 SWOT 173
VIII. 5.3 Oncology Focus 176
VIII. 6 Takeda Pharmaceuticals 177
VIII. 6.1 Business Overview 177
VIII. 6.2 SWOT 177
VIII. 7 Dendreon Corporation 179
VIII. 7.1 Business Overview 179
VIII. 7.2 SWOT 179
VIII. 8 Johnson and Johnson 183
VIII. 8.1 Business Overview 183
VIII. 8.2 SWOT 184
VIII. 8.3 Oncology Focus 190
VIII. 9 Auron Healthcare GmbH 191
VIII. 9.1 Business Overview 191
VIII. 10 Oncogenex Pharmaceuticals, Inc. 192
VIII. 10.1 Business Overview 192
VIII. 11 Agennix AG 192
VIII. 11.1 Business Overview 192
VIII. 12 GTx, Inc. 192
VIII. 12.1 Business Overview 192
VIII. 13 GlaxoSmithKline plc. 193
VIII. 13.1 Business Overview 193
VIII. 13.2 Financial Overview 194
VIII. 13.3 SWOT 194
VIII. 13.4 Oncology Focus 200

IX M&A Analysis 202
IX. 1 Key Highlights 202
IX. 2 Key Deals’ Analysis 203
IX. 2.1 Johnson & Johnson Takes Over Cougar Biotechnology 203
IX. 2.2 Endo Pharmaceuticals Takes Over Indevus Pharmaceuticals 203
IX. 2.3 Tolmar Holding Takes Over QLT USA from QLT 204
IX. 2.4 Biomarin Pharmaceutical to Acquire Lead therapeutics 204
IX. 2.5 Isis Pharmaceuticals Reacquires Rights to Cancer Drug from Eli Lilly & Co. 205
IX. 2.6 Quest PharmaTech Takes Over Late-stage Immunotherapeutic Antibody Pipeline from Paladin Labs 205
IX. 2.7 VaxOnco Takes Over Rights to Onyvax-P Cell Vaccine From Onyvax 205
IX. 2.8 GPC Biotech Merges with Agennix 205
IX. 2.9 Eli Lilly Takes Over ImClone 205
IX. 2.10 BBM Holdings Takes Over YM BioSciences 206
IX. 2.11 Sagent Pharmaceuticals Takes Over Injectable Generic Drug Applications of Spectrum Pharmaceuticals 206
IX. 3 Merger and Acquisition Deals by Geography 206
IX. 4 Merger and Acquisition Deals by Deal Size 207

X Expert Opinion 208
X. 1 Japan 208

XI Appendix 209
XI. 1 March ket Definitions 209
XI. 2 Abbreviations 209
XI. 3 Research Methodology 211
XI. 3.1 Coverage 212
XI. 3.2 Secondary Research 212
XI. 3.3 Forecasted data ing 212
XI. 3.4 Primary Research 215
XI. 3.5 Expert Panel validation 215
XI. 3.6 Contact Us 215
XI. 3.7 Disclaimer 215
XI. 3.8 Sources 2161.1 List of Data tables
Data table 1: Prostate Cancer Therapeutics March ket, Global, Staging of the Prostate Cancer, 2010 11
Data table 2: Prostate Cancer, Global, Age Related PSA Levels (ng/ml), 2010 14
Data table 3: Prostate Cancer Therapeutics March ket, Japan, Sales Value (USD Million), from 2001 to 2009 20
Data table 4: Prostate Cancer Therapeutics March ket, Japan, Annual Cost of Therapy ($), from 2001 to 2009 21
Data table 5: Prostate Cancer Therapeutics March ket, Japan, Patient Volume (’000s), from 2001 to 2009 22
Data table 6: Prostate Cancer Therapeutics March ket, Japan, Treatment Usage Patterns (’000s), from 2001 to 2009 23
Data table 7: Prostate Cancer Therapeutics March ket, Japan, Sales Value (USD Million), from 2009 to 2020 27
Data table 8: Prostate Cancer Therapeutics March ket, Japan, Annual Cost of Therapy ($), from 2009 to 2020 28
Data table 9: Prostate Cancer Therapeutics March ket, Japan, Patient Volume (’000s), from 2009 to 2020 29
Data table 10: Prostate Cancer Therapeutics March ket, Japan, Treatment Usage Patterns (’000s), from 2009 to 2020 30
Data table 11: Prostate Cancer Therapeutics March ket, Japan, Hormone-Refractory Prostate Cancer Drug Sales (USD Million), from 2001 to 2010 34
Data table 12: Prostate Cancer Therapeutics March ket, Japan, Hormone-Refractory Prostate Cancer Drug Sales (USD Million), from 2011 to 2020 34
Data table 13: Prostate Cancer Therapeutics March ket, Japan, Hormone-Dependent Prostate Cancer Drug Sales (USD Million), from 2001 to 2010 36
Data table 14: Prostate Cancer Therapeutics March ket, Japan, Hormone-Dependent Prostate Cancer Drug Sales (USD Million), from 2011 to 2020 36
Data table 15: Prostate Cancer, Global, Clinical Endpoints for Benchmarking, 2010 40
Data table 16: Prostate Cancer, Global, Chemotherapy, Safety Company Profile: Standard Care Treatment, 2010 41
Data table 17: Prostate Cancer, Global, Hormone Therapy, Safety Company Profile: Standard Care Treatment, 2010 41
Data table 18: Prostate Cancer, Japan, Benchmarking Major March keted Products, 2010 46
Data table 19: Prostate Cancer, Global, Casodex, Incidence of Adverse Effects, 2010 52
Data table 20: Prostate Cancer, Global, Lupron, Efficacy End Point for Three Products 58
Data table 21: Prostate Cancer, Global, Lupron, Incidence of Adverse Effects, 2010 59
Data table 22: Prostate Cancer, Global, Licensing Agreements, from 2009 to 2010 87
Data table 23: Prostate Cancer, Global, Technology Licensing Agreements Description, 2010 89
Data table 24: Prostate Cancer, Global, Most Promising Drugs Under Clinical Development, 2010 89
Data table 25: Prostate Cancer, Global, Pre-clinical Phase Pipeline, 2010 109
Data table 26: Prostate Cancer, Global, Phase I Pipeline, 2010 111
Data table 27: Prostate Cancer, Global, Phase II Pipeline, 2010 114
Data table 28: Prostate Cancer, Global, Phase III Pipeline, 2010 123
Data table 29: Prostate Cancer, Global, Characteristics of Ideal Drug Which Satisfies the Unmet Needs of the March ket, 2010 132
Data table 30: Prostate Cancer, Global, Description of Ideal Drug Which Satisfies the Unmet Needs of the March ket, 2010 133
Data table 31: Prostate Cancer, Johnson & Johnson, Oncology Late Stage Pipeline by Indication, 2010 190
Data table 32: Prostate Cancer, Global, Auron Healthcare, Key Pipeline Products, 2010 191
Data table 33: Prostate Cancer, Global, Merger and Acquisition Deals by Geography, 2010 2021.2

List of Figures

Chart 1: Prostate Cancer Therapeutics March ket, Global, Treatment Guidelines, 2010 19
Chart 2: Prostate Cancer Therapeutics March ket, Japan, Sales Value (USD Million), from 2001 to 2009 20
Chart 3: Prostate Cancer Therapeutics March ket, Japan, Annual Cost of Therapy ($), from 2001 to 2009 21
Chart 4: Prostate Cancer Therapeutics March ket, Japan, Patient Volume (’000s), from 2001 to 2009 22
Chart 5: Prostate Cancer Therapeutics March ket, Japan, Treatment Usage Patterns (’000s), from 2001 to 2009 23
Chart 6: Prostate Cancer Therapeutics March ket, Japan, March ket Drivers and Restraints, 2009 25
Chart 7: Prostate Cancer Therapeutics March ket, Japan, Historical data al Events Impact on the March ket, 2010 26
Chart 8: Prostate Cancer Therapeutics March ket, Japan, Sales Value (USD Million), from 2009 to 2020 27
Chart 9: Prostate Cancer Therapeutics March ket, Japan, Annual Cost of Therapy ($), from 2009 to 2020 28
Chart 10: Prostate Cancer Therapeutics March ket, Japan, Patient Volume (’000s), from 2009 to 2020 29
Chart 11: Prostate Cancer Therapeutics March ket, Japan, Treatment Usage Patterns (’000s), from 2009 to 2020 30
Chart 12: Prostate Cancer Therapeutics March ket, Japan, Future Events Expected to Impact the March ket, 2010 32
Chart 13: Prostate Cancer Therapeutics March ket, Japan, Hormone-Refractory Prostate Cancer Drug Sales (USD Million), from 2001 to 2020 33
Chart 14: Prostate Cancer Therapeutics March ket, Japan, Hormone-Dependent Prostate Cancer Drug Sales (USD Million), from 2001 to 2020 35
Chart 15: Prostate Cancer, Global, Strategic Competitor Assessment of Major March keted Drugs, Chemotherapy Drugs, 2010 43
Chart 16: Prostate Cancer, Global, Strategic Competitor Assessment of Major March keted Drugs, Hormone Therapy Drugs, 2010 44
Chart 17: Prostate Cancer Therapeutics March ket, Japan, Sales Forecasted data by Therapies, from 2001 to 2020 45
Chart 18: Prostate Cancer, Global, Taxotere, Chemical Structure 47
Chart 19: Prostate Cancer, Global, Taxotere, LCM Activities, from 2004 to 2010 49
Chart 20: Prostate Cancer, Japan, Taxotere, Sales (USD Million), from 2004 to 2020 50
Chart 21: Prostate Cancer, Global, Casodex, Chemical Structure 51
Chart 22: Prostate Cancer, Global, Casodex, LCM Activities, 1995-2010 54
Chart 23: Prostate Cancer, Japan, Casodex, Sales (USD Million), 1999-2020 55
Chart 24: Prostate Cancer, Global, Zoladex, Chemical Structure 56
Chart 25: Prostate Cancer, Japan, Zoladex, Sales Forecasted data (USD Million), from 2002 to 2020 57
Chart 26: Prostate Cancer, Global, Lupron, Chemical Structure 58
Chart 27: Prostate Cancer, Japan, Leuprolide (Lupron), Sales Forecasted data (USD Million), from 2001 to 2020 61
Chart 28: Prostate Cancer, Global, Firmagon, Chemical Structure 62
Chart 29: Prostate Cancer, Japan, Firmagon, Sales Forecasted data (USD Million), from 2009 to 2020 64
Chart 30: Prostate Cancer, Global, November atrone, Chemical Structure 65
Chart 31: Prostate Cancer, Japan, Mitoxantrone, Sales Forecasted data (USD Million), from 2001 to 2020 67
Chart 32: Prostate Cancer, Global, Emcyt, Chemical Structure 67
Chart 33: Prostate Cancer, Japan, Estramustine, Sales Forecasted data (USD Million), from 2001 to 2020 68
Chart 34: Prostate Cancer, Global, Trelstar, Chemical Structure 69
Chart 35: Prostate Cancer, Global, Eulexin, Chemical Structure 70
Chart 36: Prostate Cancer, Global, Delestrogen, Chemical Structure 72
Chart 37: Prostate Cancer, Global, Gynodiol, Chemical Structure 74
Chart 38: Prostate Cancer, Global, Estrace, Chemical Structure 75
Chart 39: Prostate Cancer, Global, Tace, Chemical Structure 76
Chart 40: Prostate Cancer, Global, Nilandrone, Chemical Structure 77
Chart 41: Prostate Cancer, Global, Premarin, Chemical Structure 78
Chart 42: Prostate Cancer, Japan, Combined sales of Trelstar, December apeptyl, Gonapeptyl, Flutamide, Estradiol, Sales Forecasted data (USD Million), from 2001 to 2020 79
Chart 43: Prostate Cancer, Global, Clinical Trials by Therapy, 2010 80
Chart 44: Prostate Cancer, Global, Clinical Trials by Phase of Development, 2010 81
Chart 45: Prostate Cancer, Global, Pipeline by Mechanism of Action, 2010 82
Chart 46: Prostate Cancer, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2010 83
Chart 47: Prostate Cancer, Global, Technology Trends Description of Pipeline Drugs, 2010 84
Chart 48: Prostate Cancer, Global, Licensing Agreements by Phase of Development, from 2009 to 2010 85
Chart 49: Prostate Cancer, Global, Licensing Agreements by Geography, 2010 88
Chart 50: Prostate Cancer, Japan, Provenge, Sales Forecasted data (USD Million), 2016-2020 92
Chart 51: Prostate Cancer, Japan, Jevtana, Sales Forecasted data (USD Million), 2013-2020 94
Chart 52: Prostate Cancer, Global, Aflibercept, Chemical Structure 95
Chart 53: Prostate Cancer, Japan, Aflibercept, Sales Forecasted data (USD Million), 2016-2020 97
Chart 54: Prostate Cancer, Japan, Ipilimumab, Sales Forecasted data (USD Million), 2014-2020 99
Chart 55: Prostate Cancer, Global, Abiraterone, Chemical Structure 100
Chart 56: Prostate Cancer, Japan, Abiraterone, Sales Forecasted data (USD Million), 2015-2020 102
Chart 57: Prostate Cancer, Global, Zibotentan, Chemical Structure 102
Chart 58: Prostate Cancer, Japan, Zibotentan, Sales Forecasted data (USD Million), 2015-2020 104
Chart 59: Prostate Cancer, Japan, Sprycel, Sales Forecasted data (USD Million), 2013-2020 105
Chart 60: Prostate Cancer, Global, MDV3100, Chemical Structure 106
Chart 61: Prostate Cancer, Japan, MDV3100, Sales Forecasted data (USD Million), 2015-2020 108
Chart 62: Prostate Cancer, Global, Median Overall Survival for Hormone-independent Metastatic Prostate Cancer Patients, 2010 126
Chart 63: Prostate Cancer, Global, Median Overall Survival for Hormone-dependent Metastatic Prostate Cancer Patients, 2010 127
Chart 64: Prostate Cancer, Global, Hormone-dependent Metastatic Prostate Cancer Patients Achieving Castrate Level Testosterone Level in 28-30 Days (%), 2010 127
Chart 65: Prostate Cancer, Japan, Prostate Cancer, Opportunity and Unmet Need, 2010 128
Chart 66: Prostate Cancer, Japan, Hormone-independent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010 131
Chart 67: Prostate Cancer, Japan, Hormone-dependent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010 132
Chart 68: Prostate Cancer, Global, Key Events Impacting the Future March ket 134
Chart 69: Prostate Cancer, Japan, Implications for Future March ket Competition, 2010 135
Chart 70: Prostate Cancer, Global, Future Players in the March ket, 2010 137
Chart 71:Prostate Cancer, Sanofi-aventis, Major Pharmaceutical Drugs 2010 139
Chart 72: Prostate Cancer, Sanofi-aventis Pasteur, Diseases Under Each Vaccination Area 2010 140
Chart 73: Prostate Cancer, Global, Sanofi-aventis, SWOT, 2010 141
Chart 74: Prostate Cancer, Sanofi-aventis, Therapeutic Segment Share of Pipeline 2010 146
Chart 75: Prostate Cancer, Global, Pfizer, SWOT 2010 148
Chart 76: Prostate Cancer, Pfizer, Distribution of Pipeline by Phase, 2010 154
Chart 77: Prostate Cancer, Pfizer, Therapeutic Segment Share of Pipeline 2010 155
Chart 78: Prostate Cancer, Astrazeneca, Key Products Portfolio 2010 157
Chart 79: Prostate Cancer, Global, AstraZeneca, SWOT 2010 158
Chart 80: Prostate Cancer, AstraZeneca, Oncology Products for Different Cancers 2010 162
Chart 81: Prostate Cancer, AstraZeneca, Distribution of Pipeline, by Phase, 2010 162
Chart 82: Prostate Cancer, AstraZeneca, Therapeutic Segment Share of Pipeline 2010 163
Chart 83: Prostate Cancer, Bristol-Myers Squibb, Key Products Portfolio 2010 164
Chart 84: Prostate Cancer, Global, Firms Bristol-Myers Squibb, SWOT, 2010 165
Chart 85: Prostate Cancer, Bristol-Myers Squibb, Distribution of Pipeline by Phase, 2010 171
Chart 86: Prostate Cancer, Bristol-Myers Squibb, Therapeutic Segment Share of Pipeline 2010 172
Chart 87: Prostate Cancer, Global, Medivation, SWOT 2010 173
Chart 88: Prostate Cancer, Global, Takeda Pahrmaceuticals, SWOT 2010 177
Chart 89: Prostate Cancer, Global, Dendreon Corporation, SWOT 2010 179
Chart 90: Prostate Cancer, Global, Johnson and Johnson, SWOT 2010 184
Chart 91: Prostate Cancer, Johnson & Johnson, Late Stage Pipeline by Therapy Area, 2010 191
Chart 92: Prostate Cancer, Global, GlaxoSmithKline, SWOT 2010 194
Chart 93: Prostate Cancer, GlaxoSmithKline, Distribution of Pipeline by Phase, 2010 200
Chart 94: Prostate Cancer, GlaxoSmithKline, Therapeutic Segment Share of Pipeline 2010 201
Chart 95: Prostate Cancer, Global, Merger and Acquisition Deals by Geography of Target Firms, 2010 206
Chart 96: Prostate Cancer, Global, Merger and Acquisition Deals by Deal Size, 2010 207
Chart 97: Prostate Cancer, Japan, Key Data Inputs from KOL Interviews, 2010 208
Chart 98: GlobalData March ket Forecasted data ing Model 214

Companies mentioned
Sanofi-aventis
Pfizer Inc.
AstraZeneca
Bristol-Myers Squibb
Medivation
Takeda Pharmaceuticals
Dendreon Corporation
Johnson and Johnson
Auron Healthcare GmbH
Oncogenex Pharmaceuticals, Inc.
Agennix AG
GTx, Inc.
GlaxoSmithKline plc.